<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23000686</PMID>
      <DateCompleted>
        <Year>2012</Year>
        <Month>12</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1474-1784</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2012</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Nature reviews. Drug discovery</Title>
          <ISOAbbreviation>Nat Rev Drug Discov</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Targeting the TGFβ signalling pathway in disease.</ArticleTitle>
        <Pagination>
          <StartPage>790</StartPage>
          <EndPage>811</EndPage>
          <MedlinePgn>790-811</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/nrd3810</ELocationID>
        <Abstract>
          <AbstractText>Many drugs that target transforming growth factor-β (TGFβ) signalling have been developed, some of which have reached Phase III clinical trials for a number of disease applications. Preclinical and clinical studies indicate the utility of these agents in fibrosis and oncology, particularly in augmentation of existing cancer therapies, such as radiation and chemotherapy, as well as in tumour vaccines. There are also reports of specialized applications, such as the reduction of vascular symptoms of Marfan syndrome. Here, we consider why the TGFβ signalling pathway is a drug target, the potential clinical applications of TGFβ inhibition, the issues arising with anti-TGFβ therapy and how these might be tackled using personalized approaches to dosing, monitoring of biomarkers as well as brief and/or localized drug-dosing regimens.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Akhurst</LastName>
            <ForeName>Rosemary J</ForeName>
            <Initials>RJ</Initials>
            <AffiliationInfo>
              <Affiliation>Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94158, USA. RAkhurst@cc.ucsf.edu</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hata</LastName>
            <ForeName>Akiko</ForeName>
            <Initials>A</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA116019</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 GM060514</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL078564</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA082103</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 AR050440</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL108317</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R21 CA164772</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2012</Year>
          <Month>09</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Nat Rev Drug Discov</MedlineTA>
        <NlmUniqueID>101124171</NlmUniqueID>
        <ISSNLinking>1474-1776</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018125">Receptors, Transforming Growth Factor beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018125" MajorTopicYN="N">Receptors, Transforming Growth Factor beta</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2012</Year>
          <Month>9</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2012</Year>
          <Month>9</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2012</Year>
          <Month>12</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23000686</ArticleId>
        <ArticleId IdType="mid">NIHMS421715</ArticleId>
        <ArticleId IdType="pmc">PMC3520610</ArticleId>
        <ArticleId IdType="doi">10.1038/nrd3810</ArticleId>
        <ArticleId IdType="pii">nrd3810</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Schmierer B, Hill CS. TGFβ-SMAD signal transduction: molecular specificity and functional flexibility. Nature Rev. Mol. Cell Biol. 2007;8:970–982.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18000526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Derynck R, Miyazono K, editors. The TGF-β Family. Cold Spring Harbor Press; 2008. </Citation>
        </Reference>
        <Reference>
          <Citation>Derynck R, Akhurst RJ. Differentiation plasticity regulated by TGF-β family proteins in development and disease. Nature Cell Biol. 2007;9:1000–1004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17762890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P. The polarization of immune cells in the tumour environment by TGFβ. Nature Rev. Immunol. 2010;10:554–567.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3885992</ArticleId>
            <ArticleId IdType="pubmed">20616810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao JH, et al.  Genetic variants of Tgfb1 act as context-dependent modifiers of mouse skin tumor susceptibility. Proc. Natl Acad. Sci. USA. 2006;103:8125–8130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1472440</ArticleId>
            <ArticleId IdType="pubmed">16702541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo X, Wang XF. Signaling cross-talk between TGF-β/BMP and other pathways. Cell Res. 2009;19:71–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3606489</ArticleId>
            <ArticleId IdType="pubmed">19002158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conidi A, et al.  Few Smad proteins and many Smad-interacting proteins yield multiple functions and action modes in TGFβ/BMP signaling in vivo. Cytokine Growth Factor Rev. 2011;22:287–300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22119658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akhurst RJ. TGFβ signaling in health and disease. Nature Genet. 2004;36:790–792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15284845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freimuth J, et al.  Epistatic interactions between Tgfb1 and genetic loci, Tgfbm2 and Tgfbm3, determine susceptibility to an asthmatic stimulus. Proc. Natl Acad. Sci. USA.  in the press.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3497801</ArticleId>
            <ArticleId IdType="pubmed">23064636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anscher MS, et al.  Small molecular inhibitor of transforming growth factor-β protects against development of radiation-induced lung injury. Int. J. Radiat. Oncol. Biol. Phys. 2008;71:829–837.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18411002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neptune ER, et al.  Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome. Nature Genet. 2003;33:407–411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12598898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Habashi JP, et al.  Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312:117–121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1482474</ArticleId>
            <ArticleId IdType="pubmed">16601194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts AB, Wakefield LM. The two faces of transforming growth factor β in carcinogenesis. Proc. Natl Acad. Sci. USA. 2003;100:8621–8623.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC166359</ArticleId>
            <ArticleId IdType="pubmed">12861075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Massague J. TGFβ in cancer. Cell. 2008;134:215–230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3512574</ArticleId>
            <ArticleId IdType="pubmed">18662538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levy L, Hill CS. Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev. 2006;17:41–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16310402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hawinkels LJ, Ten Dijke P. Exploring anti-TGF-β therapies in cancer and fibrosis. Growth Factors. 2011;29:140–152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21718111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harradine KA, Akhurst RJ. Mutations of TGFβ signaling molecules in human disease. Ann. Med. 2006;38:403–414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17008304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Millan FA, Denhez F, Kondaiah P, Akhurst RJ. Embryonic gene expression patterns of TGF β1, β2 and β3 suggest different developmental functions in vivo. Development. 1991;111:131–143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1707784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kulkarni AB, et al.  Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl Acad. Sci. USA. 1993;90:770–774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC45747</ArticleId>
            <ArticleId IdType="pubmed">8421714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shull MM, et al.  Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature. 1992;359:693–699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3889166</ArticleId>
            <ArticleId IdType="pubmed">1436033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dickson MC, et al.  Defective haematopoiesis and vasculogenesis in transforming growth factor-β1 knock out mice. Development. 1995;121:1845–1854.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7600998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanford LP, et al.  TGFβ2 knockout mice have multiple developmental defects that are non-overlapping with other TGFβ knockout phenotypes. Development. 1997;124:2659–2670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3850286</ArticleId>
            <ArticleId IdType="pubmed">9217007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Proetzel G, et al.  Transforming growth factor-β3 is required for secondary palate fusion. Nature Genet. 1995;11:409–414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3855390</ArticleId>
            <ArticleId IdType="pubmed">7493021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich JE. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-β in a chemically defined system. J. Biol. Chem. 1994;269:26775–26782.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7929413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munger JS, et al.  The integrin αvβ6 binds and activates latent TGF β1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999;96:319–328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10025398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi M, et al.  Latent TGF-β structure and activation. Nature. 2011;474:343–349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4717672</ArticleId>
            <ArticleId IdType="pubmed">21677751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi Y, Massague J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell. 2003;113:685–700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12809600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis-Dusenbery BN, Hata A. Smad-mediated miRNA processing: a critical role for a conserved RNA sequence. RNA Biol. 2011;8:71–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3230544</ArticleId>
            <ArticleId IdType="pubmed">21289485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oft M, et al.  TGF-β1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 1996;10:2462–2477.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8843198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Massague J, Gomis RR. The logic of TGFβ signaling. FEBS Lett. 2006;580:2811–2820.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16678165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Massague J. How cells read TGF-β signals. Nature Rev. Mol. Cell Biol. 2000;1:169–178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11252892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mehra A, Wrana JL. TGF-β and the Smad signal transduction pathway. Biochem. Cell Biol. 2002;80:605–622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12440701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Padua D, Massague J. Roles of TGFβ in metastasis. Cell Res. 2009;19:89–102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19050696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heldin CH, Landstrom M, Moustakas A. Mechanism of TGF-β signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr. Opin. Cell Biol. 2009;21:166–176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19237272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dooley S, ten Dijke P. TGF-β in progression of liver disease. Cell Tissue Res. 2012;347:245–256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3250614</ArticleId>
            <ArticleId IdType="pubmed">22006249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pardali E, Ten Dijke P. TGFβ signaling and cardiovascular diseases. Int. J. Biol. Sci. 2012;8:195–213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3258560</ArticleId>
            <ArticleId IdType="pubmed">22253564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nature Genet. 2001;29:117–129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11586292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coffey RJ, Jr, et al.  Growth modulation of mouse keratinocytes by transforming growth factors. Cancer Res. 1988;48:1596–1602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2449957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gomis RR, et al.  A FoxO-Smad synexpression group in human keratinocytes. Proc. Natl Acad. Sci. USA. 2006;103:12747–12752.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1568919</ArticleId>
            <ArticleId IdType="pubmed">16908841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegel PM, Shu W, Massague J. Mad upregulation and Id2 repression accompany transforming growth factor (TGF)-β-mediated epithelial cell growth suppression. J. Biol. Chem. 2003;278:35444–35450.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12824180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akhurst RJ. The paradoxical TGF-β vasculopathies. Nature Genet. 2012;44:838–839.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3543110</ArticleId>
            <ArticleId IdType="pubmed">22836090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure — an obstacle in cancer therapy. Nature Rev. Cancer. 2004;4:806–813.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15510161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mani SA, et al.  The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2728032</ArticleId>
            <ArticleId IdType="pubmed">18485877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salnikov AV, et al.  Inhibition of TGF-β modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma. Lab. Invest. 2005;85:512–521.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15711566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willis BC, et al.  Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-β1: potential role in idiopathic pulmonary fibrosis. Am. J. Pathol. 2005;166:1321–1332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1606388</ArticleId>
            <ArticleId IdType="pubmed">15855634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim KK, et al.  Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl Acad. Sci. USA. 2006;103:13180–13185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1551904</ArticleId>
            <ArticleId IdType="pubmed">16924102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goumans MJ, van Zonneveld AJ, ten Dijke P. Transforming growth factor β-induced endothelial-to-mesenchymal transition: a switch to cardiac fibrosis? Trends Cardiovasc. Med. 2008;18:293–298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19345316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A. Targeted disruption of TGF-β1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J. Clin. Invest. 2003;112:1486–1494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC259132</ArticleId>
            <ArticleId IdType="pubmed">14617750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lan HY. Diverse roles of TGF-β/Smads in renal fibrosis and inflammation. Int. J. Biol. Sci. 2011;7:1056–1067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3174390</ArticleId>
            <ArticleId IdType="pubmed">21927575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu K, et al.  SM16, an orally active TGFβ type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Arterioscler. Thromb. Vasc. Biol. 2008;28:665–671.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18202322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishimura G, et al.  δEF1 mediates TGF-β signaling in vascular smooth muscle cell differentiation. Dev. Cell. 2006;11:93–104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16824956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diebold RJ, et al.  Early-onset multifocal inflammation in the transforming growth factor β1-null mouse is lymphocyte mediated. Proc. Natl Acad. Sci. USA. 1995;92:12215–12219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC40327</ArticleId>
            <ArticleId IdType="pubmed">8618872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rubtsov YP, Rudensky AY. TGFβ signalling in control of T-cell-mediated self-reactivity. Nature Rev. Immunol. 2007;7:443–453.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17525753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramesh S, Wildey GM, Howe PH. Transforming growth factor β (TGFβ)-induced apoptosis: the rise and fall of Bim. Cell Cycle. 2009;8:11–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3191464</ArticleId>
            <ArticleId IdType="pubmed">19106608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maruyama T, et al.  Control of the differentiation of regulatory T cells and TH17 cells by the DNA-binding inhibitor Id3. Nature Immunol. 2011;12:86–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3140164</ArticleId>
            <ArticleId IdType="pubmed">21131965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamaguchi Y, Tsumura H, Miwa M, Inaba K. Contrasting effects of TGF-β1 and TNF-α on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells. 1997;15:144–153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9090791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato K, et al.  TGF-β1 reciprocally controls chemotaxis of human peripheral blood monocyte-derived dendritic cells via chemokine receptors. J. Immunol. 2000;164:2285–2295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10679062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bettelli E, et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235–238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16648838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mangan PR, et al.  Transforming growth factor-β induces development of the TH17 lineage. Nature. 2006;441:231–234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16648837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutcher I, et al.  Autocrine transforming growth factor-β1 promotes in vivo TH17 cell differentiation. Immunity. 2011;34:396–408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3690311</ArticleId>
            <ArticleId IdType="pubmed">21435587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Annunziato F, Romagnani S. Mouse T helper 17 phenotype: not so different than in man after all. Cytokine. 2011;56:112–115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21813287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Das J, et al.  Transforming growth factor β is dispensable for the molecular orchestration of TH17 cell differentiation. J. Exp. Med. 2009;206:2407–2416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2768861</ArticleId>
            <ArticleId IdType="pubmed">19808254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghoreschi K, et al.  Generation of pathogenic TH17 cells in the absence of TGF-β signalling. Nature. 2010;467:967–971.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3108066</ArticleId>
            <ArticleId IdType="pubmed">20962846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laouar Y, Sutterwala FS, Gorelik L, Flavell RA. Transforming growth factor-β controls T helper type 1 cell development through regulation of natural killer cell interferon-γ. Nature Immunol. 2005;6:600–607.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15852008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549–555.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12401408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schlingensiepen R, et al.  Intracerebral and intrathecal infusion of the TGF-β2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety. Oligonucleotides. 2005;15:94–104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15989424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schlingensiepen KH, et al.  Targeted tumor therapy with the TGF-β2 antisense compound AP 12009. Cytokine Growth Factor Rev. 2006;17:129–139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16377233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jachimczak P, et al.  The effect of transforming growth factor-β2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J. Neurosurg. 1993;78:944–951.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8487077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schlingensiepen KH, et al.  Transforming growth factor-β2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Cancer Sci. 2011;102:1193–1200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21366804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llopiz D, et al.  Peptide inhibitors of transforming growth factor-β enhance the efficacy of antitumor immunotherapy. Int. J. Cancer. 2009;125:2614–2623.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19530254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ezquerro IJ, et al.  A synthetic peptide from transforming growth factor β type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. Cytokine. 2003;22:12–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12946101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nam JS, et al.  An anti-transforming growth factor β antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res. 2008;68:3835–3843.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2587151</ArticleId>
            <ArticleId IdType="pubmed">18483268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ganapathy V, et al.  Targeting the transforming growth factor-β pathway inhibits human basal-like breast cancer metastasis. Mol. Cancer. 2010;9:122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2890606</ArticleId>
            <ArticleId IdType="pubmed">20504320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bouquet F, et al.  TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin. Cancer Res. 2011;17:6754–6765.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3724539</ArticleId>
            <ArticleId IdType="pubmed">22028490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodon Ahnert J, et al.  First human dose (FHD) study of the oral transforming growth factor-β receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma. J. Clin. Oncol. 2011;29 Abstract 3011.</Citation>
        </Reference>
        <Reference>
          <Citation>Schlingensiepen KH, Fischer-Blass B, Schmaus S, Ludwig S. Antisense therapeutics for tumor treatment: the TGF-β2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res. 2008;177:137–150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18084956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oettle H, et al.  Final results of a phase I/II study in patients with pancreatic cancer, malignant melanoma, and colorectal carcinoma with trabedersen. J. Clin. Oncol. 2012;30 Abstract 4034.</Citation>
        </Reference>
        <Reference>
          <Citation>Nemunaitis J, et al.  Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther. 2009;16:620–624.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19287371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bazhenova L, Carrier E, Shawler D, Fakhrai H. Long-term survival in a phase II study of belagenpumatucel-L (antisense TGFβ vaccine) in non small-cell lung cancer (NSCLC) Cancer Res. 2012;72 Abstract 5367.</Citation>
        </Reference>
        <Reference>
          <Citation>Mead AL, Wong TT, Cordeiro MF, Anderson IK, Khaw PT. Evaluation of anti-TGF-β2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest. Ophthalmol. Vis. Sci. 2003;44:3394–3401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12882787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CAT-152 0201 Trabeculectomy Study Group  CAT-152 trabeculectomy study. Ophthalmology. 2007;114:1950.</Citation>
        </Reference>
        <Reference>
          <Citation>Lonning S, Mannick J, McPherson JM. Antibody targeting of TGF-β in cancer patients. Curr. Pharm. Biotechnol. 2011;12:2176–2189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21619535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trachtman H, et al.  A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int. 2011;79:1236–1243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3257033</ArticleId>
            <ArticleId IdType="pubmed">21368745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morris JC, et al.  Phase I/II study of GC1008: a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC) J. Clin. Oncol. 2008;26 Abstract 9028.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhong Z, et al.  Anti-transforming growth factor β receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin. Cancer Res. 2010;16:1191–1205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20145179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Aarsen LA, et al.  Antibody-mediated blockade of integrin αvβ6 inhibits tumor progression in vivo by a transforming growth factor-β-regulated mechanism. Cancer Res. 2008;68:561–570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18199553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muraoka RS, et al.  Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 2002;109:1551–1559.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC151012</ArticleId>
            <ArticleId IdType="pubmed">12070302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu A, Miao M, Schoeb TR, Agarwal A, Murphy-Ullrich JE. Blockade of TSP1-dependent TGF-β activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy. Am. J. Pathol. 2011;178:2573–2586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3124297</ArticleId>
            <ArticleId IdType="pubmed">21641382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-β signalling inhibitors for cancer therapy. Nature Rev. Drug Discov. 2004;3:1011–1022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15573100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonafoux D, Lee WC. Strategies for TGF-β modulation: a review of recent patents. Expert Opin. Ther. Pat. 2009;19:1759–1769.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19939191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saunier EF, Akhurst RJ. TGFβ inhibition for cancer therapy. Curr. Cancer Drug Targets. 2006;6:519–532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17017875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akhurst RJ. Large- and small-molecule inhibitors of transforming growth factor-beta signaling. Curr. Opin. Investig. Drugs. 2006;7:513–521.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16784021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Washio H, et al.  Transcriptional inhibition of hypertrophic scars by a gene silencer, pyrrole-imidazole polyamide, targeting the TGF-β1 promoter. J. Invest. Dermatol. 2011;131:1987–1995.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21654833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen M, et al.  Pretranscriptional regulation of Tgf-β1 by PI polyamide prevents scarring and accelerates wound healing of the cornea after exposure to alkali. Mol. Ther. 2010;18:519–527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2839444</ArticleId>
            <ArticleId IdType="pubmed">19920805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen HY, et al.  The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential. Diabetes. 2011;60:590–601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3028360</ArticleId>
            <ArticleId IdType="pubmed">20980457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kapoor S. Smad7 gene transfer therapy: therapeutic applications beyond colonic fibrosis. Eur. J. Clin. Invest. 2008;38:876–877. author reply 878-880.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19021708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheridan C. Gene therapy finds its niche. Nature Biotech. 2011;29:121–128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21301435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foster AE, et al.  Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-β receptor. J. Immunother. 2008;31:500–505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2745436</ArticleId>
            <ArticleId IdType="pubmed">18463534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rainusso N, et al.  Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Ther. 2012;19:212–217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22173710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakazawa Y, et al.  PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol. Ther. 2011;19:2133–2143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3242651</ArticleId>
            <ArticleId IdType="pubmed">21772253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmed N, et al.  HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin. Cancer Res. 2010;16:474–485.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3682507</ArticleId>
            <ArticleId IdType="pubmed">20068073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmed N, et al.  Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 2007;67:5957–5964.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17575166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laverty HG, et al.  Effects of avotermin (transforming growth factor β3) in a clinically relevant pig model of long, full-thickness incisional wounds. J. Cutan. Med. Surg. 2010;14:223–232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20868619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohn RD, et al.  Angiotensin II type 1 receptor blockade attenuates TGF-β-induced failure of muscle regeneration in multiple myopathic states. Nature Med. 2007;13:204–210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3138130</ArticleId>
            <ArticleId IdType="pubmed">17237794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Podowski M, et al.  Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice. J. Clin. Invest. 2012;122:229–240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3248282</ArticleId>
            <ArticleId IdType="pubmed">22182843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lanz TV, et al.  Angiotensin II sustains brain inflammation in mice via TGF-β. J. Clin. Invest. 2010;120:2782–2794.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2912186</ArticleId>
            <ArticleId IdType="pubmed">20628203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou H, Latham CW, Zander DS, Margolin SB, Visner GA. Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts. J. Heart Lung Transplant. 2005;24:1577–1585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16210133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taniguchi H, et al.  The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir. Res. 2011;12:93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3160381</ArticleId>
            <ArticleId IdType="pubmed">21756364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noble PW, et al.  Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760–1769.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21571362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grainger DJ, et al.  The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nature Med. 1995;1:74–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7584958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cui W, et al.  TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell. 1996;86:531–542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8752208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bierie B, Moses HL. Gain or loss of TGFβ signaling in mammary carcinoma cells can promote metastasis. Cell Cycle. 2009;8:3319–3327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19806012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bierie B, et al.  Abrogation of TGF-β signaling enhances chemokine production and correlates with prognosis in human breast cancer. J. Clin. Invest. 2009;119:1571–1582.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2689133</ArticleId>
            <ArticleId IdType="pubmed">19451693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larsson J, et al.  Abnormal angiogenesis but intact hematopoietic potential in TGF-β type I receptor-deficient mice. EMBO J. 2001;20:1663–1673.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC145465</ArticleId>
            <ArticleId IdType="pubmed">11285230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akhurst RJ. TGF-β antagonists: why suppress a tumor suppressor? J. Clin. Invest. 2002;109:1533–1536.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC151022</ArticleId>
            <ArticleId IdType="pubmed">12070299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderton MJ, et al.  Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol. Pathol. 2011;39:916–924.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21859884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frazier K, et al.  Inhibition of ALK5 signaling induces physeal dysplasia in rats. Toxicol. Pathol. 2007;35:284–295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17366323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goudie DR, et al.  Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1. Nature Genet. 2011;43:365–369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21358634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chapman PB, et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011;364:2507–2516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3549296</ArticleId>
            <ArticleId IdType="pubmed">21639808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnault JP, et al.  Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J. Clin. Oncol. 2009;27:e59–e61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19597016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esser AC, Abril A, Fayne S, Doyle JA. Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J. Am. Acad. Dermatol. 2004;50:S75–S77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15097933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su F, et al.  RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 2012;366:207–215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3724537</ArticleId>
            <ArticleId IdType="pubmed">22256804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnault JP, et al.  Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin. Cancer Res. 2012;18:263–272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22096025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741–4751.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3176718</ArticleId>
            <ArticleId IdType="pubmed">20531305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shipitsin M, et al.  Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007;11:259–273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17349583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ikushima H, et al.  Autocrine TGF-β signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell. 2009;5:504–514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19896441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Penuelas S, et al.  TGF-β increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell. 2009;15:315–327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19345330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bragado P, et al.  Microenvironmental signals dictate disseminated tumor cells (DTCs) fate through regulation of TGFβII and p38α. Cancer Res. 2012;72(Suppl. 1) Abstract 5234.</Citation>
        </Reference>
        <Reference>
          <Citation>Biswas T, Yang J, Zhao L, Sun LZ. Development of murine models of breast cancer metastasis for the evaluation of the efficacy of TGF-β inhibitors as therapeutic agents. Cancer Res. 2012;72(Suppl. 1) Abstract 1366.</Citation>
        </Reference>
        <Reference>
          <Citation>Ohmori T, Yang JL, Price JO, Arteaga CL. Blockade of tumor cell transforming growth factor-βs enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. Exp. Cell Res. 1998;245:350–359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9851876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ehata S, et al.  Transforming growth factor-β decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells. Oncogene. 2011;30:1693–1705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21132002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang B, et al.  Transforming growth factor-β can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res. 2007;67:8643–8652.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2427144</ArticleId>
            <ArticleId IdType="pubmed">17875704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quante M, et al.  Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 2011;19:257–272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3060401</ArticleId>
            <ArticleId IdType="pubmed">21316604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bandyopadhyay A, et al.  Doxorubicin in combination with a small TGFβ inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS ONE. 2010;5:e10365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2860989</ArticleId>
            <ArticleId IdType="pubmed">20442777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeuchi K, et al.  TGF-β inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS ONE. 2010;5:e9870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2845613</ArticleId>
            <ArticleId IdType="pubmed">20360846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin JJ, et al.  TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 1999;103:197–206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC407876</ArticleId>
            <ArticleId IdType="pubmed">9916131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shinto O, et al.  Combination effect of a TGF-β receptor kinase inhibitor with 5-FU analog S1 on lymph node metastasis of scirrhous gastric cancer in mice. Cancer Sci. 2010;101:1846–1852.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20518790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kano MR, et al.  Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling. Proc. Natl Acad. Sci. USA. 2007;104:3460–3465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1800736</ArticleId>
            <ArticleId IdType="pubmed">17307870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Zeng G. Cancer and innate immune system interactions: translational potentials for cancer immunotherapy. J. Immunother. 2012;35:299–308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3331796</ArticleId>
            <ArticleId IdType="pubmed">22495387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, et al.  Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor β-insensitive CD8+ T cells. Clin. Cancer Res. 2010;16:164–173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20028741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Q, et al.  Blockade of transforming growth factor-β signaling in tumor-reactive CD8+ T cells activates the antitumor immune response cycle. Mol. Cancer Ther. 2006;5:1733–1743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16891459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Connolly EC, et al.  Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long term TβRI/II kinase inhibition with LY2109761. Cancer Res. 2011;71:1–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3059399</ArticleId>
            <ArticleId IdType="pubmed">21282335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang M, et al.  Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res. 2011;71:7155–7167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22006998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barcellos-Hoff MH, Akhurst RJ. Transforming growth factor-β in breast cancer: too much, too late. Breast Cancer Res. 2009;11:202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2687712</ArticleId>
            <ArticleId IdType="pubmed">19291273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kirshner J, et al.  Inhibition of transforming growth factor-β1 signaling attenuates ataxia telangiectasia mutated activity in response to genotoxic stress. Cancer Res. 2006;66:10861–10869.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17090522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou L, et al.  Reduced SMAD7 leads to overactivation of TGF-β signaling in MDS that can be reversed by a specific inhibitor of TGF-β receptor I kinase. Cancer Res. 2011;71:955–963.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3032816</ArticleId>
            <ArticleId IdType="pubmed">21189329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cerri S, Spagnolo P, Luppi F, Richeldi L. Management of idiopathic pulmonary fibrosis. Clin. Chest Med. 2012;33:85–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22365248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheppard D. Transforming growth factor β: a central modulator of pulmonary and airway inflammation and fibrosis. Proc. Am. Thorac. Soc. 2006;3:413–417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2658705</ArticleId>
            <ArticleId IdType="pubmed">16799084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chapman HA. Epithelial-mesenchymal interactions in pulmonary fibrosis. Annu. Rev. Physiol. 2011;73:413–435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21054168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamada M, et al.  Gene transfer of soluble transforming growth factor type II receptor by in vivo electroporation attenuates lung injury and fibrosis. J. Clin. Pathol. 2007;60:916–920.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1994490</ArticleId>
            <ArticleId IdType="pubmed">17018685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arribillaga L, et al.  Therapeutic effect of a peptide inhibitor of TGF-β on pulmonary fibrosis. Cytokine. 2011;53:327–333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21185199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crunkhorn S. Deal watch: Biogen acquires Stromedix to pursue novel fibrosis therapy. Nature Rev. Drug Discov. 2012;11:260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22460113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allison M. Stromedix acquisition signals growing interest in fibrosis. Nature Biotech. 2012;30:375–376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22565944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 2006;69:213–217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16408108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fragiadaki M, Mason RM. Epithelial-mesenchymal transition in renal fibrosis — evidence for and against. Int. J. Exp. Pathol. 2011;92:143–150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3101487</ArticleId>
            <ArticleId IdType="pubmed">21554437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alan C, Kocoglu H, Altintas R, Alici B, Resit Ersay A. Protective effect of decorin on acute ischaemia-reperfusion injury in the rat kidney. Arch. Med. Sci. 2011;7:211–216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3258707</ArticleId>
            <ArticleId IdType="pubmed">22291758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim DS, et al.  Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation. 2001;103:789–791.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2779524</ArticleId>
            <ArticleId IdType="pubmed">11171784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Rooij E, Olson EN. Searching for miR-acles in cardiac fibrosis. Circ. Res. 2009;104:138–140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2747251</ArticleId>
            <ArticleId IdType="pubmed">19179664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merkel PA, et al.  Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. Arthritis Rheum. 2008;59:699–705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3887555</ArticleId>
            <ArticleId IdType="pubmed">18438905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCaffrey TA. TGF-β signaling in atherosclerosis and restenosis. Front. Biosci. (Schol. Ed.) 2009;1:236–245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19482699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedl R, et al.  Intimal hyperplasia and expression of transforming growth factor-β1 in saphenous veins and internal mammary arteries before coronary artery surgery. Ann. Thorac. Surg. 2004;78:1312–1318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15464491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ranjzad P, Salem HK, Kingston PA. Adenovirus-mediated gene transfer of fibromodulin inhibits neointimal hyperplasia in an organ culture model of human saphenous vein graft disease. Gene Ther. 2009;16:1154–1162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19474808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kapur NK, et al.  Inhibition of transforming growth factor-β restores endothelial thromboresistance in vein grafts. J. Vasc. Surg. 2011;54:1117–1123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3188354</ArticleId>
            <ArticleId IdType="pubmed">21803524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramirez F, Dietz HC. Marfan syndrome: from molecular pathogenesis to clinical treatment. Curr. Opin. Genet. Dev. 2007;17:252–258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17467262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siriwardena D, et al.  Human antitransforming growth factor β2 monoclonal antibody — a new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study. Ophthalmology. 2002;109:427–431.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11874742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukuda K, Chikama T, Takahashi M, Nishida T. Long-term follow-up after lamellar keratoplasty in a patient with bilateral idiopathic corneal keloid. Cornea. 2011;30:1491–1494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22067103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benzinou M, et al.  Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia. Nature Commun. 2012;3:616.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3509798</ArticleId>
            <ArticleId IdType="pubmed">22233626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonyadi M, et al.  Mapping of a major genetic modifier of embryonic lethality in TGFβ1 knockout mice. Nature Genet. 1997;15:207–211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9020852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farrington DL, et al.  Development and validation of a phosphorylated SMAD ex vivo stimulation assay. Biomarkers. 2007;12:313–330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17453744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu W, et al.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 2006;203:1701–1711.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2118339</ArticleId>
            <ArticleId IdType="pubmed">16818678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McClymont SA, et al.  Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J. Immunol. 2011;186:3918–3926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3091943</ArticleId>
            <ArticleId IdType="pubmed">21368230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>You S, et al.  Adaptive TGF-β-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc. Natl Acad. Sci. USA. 2007;104:6335–6340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1851030</ArticleId>
            <ArticleId IdType="pubmed">17389382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clay TM, Hobeika AC, Mosca PJ, Lyerly HK, Morse MA. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin. Cancer Res. 2001;7:1127–1135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11350875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baselga J, et al.  TGF-β signalling-related markers in cancer patients with bone metastasis. Biomarkers. 2008;13:217–236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18270872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bornstein S, et al.  Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation. J. Clin. Invest. 2009;119:3408–3419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2769185</ArticleId>
            <ArticleId IdType="pubmed">19841536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu SL, et al.  Loss of transforming growth factor-β type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev. 2006;20:1331–1342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1472907</ArticleId>
            <ArticleId IdType="pubmed">16702406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gomis RR, Alarcon C, Nadal C, Van Poznak C, Massague J. C/EBPβ at the core of the TGFβ cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell. 2006;10:203–214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16959612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Micalizzi DS, et al.  The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-β signaling. J. Clin. Invest. 2009;119:2678–2690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2735914</ArticleId>
            <ArticleId IdType="pubmed">19726885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hannigan A, et al.  Epigenetic downregulation of human disabled homolog 2 switches TGF-β from a tumor suppressor to a tumor promoter. J. Clin. Invest. 2010;120:2842–2857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2912175</ArticleId>
            <ArticleId IdType="pubmed">20592473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Law BK, et al.  Rapamycin potentiates transforming growth factor β-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol. Cell. Biol. 2002;22:8184–8198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC134072</ArticleId>
            <ArticleId IdType="pubmed">12417722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Engelman JA, Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr. Opin. Genet. Dev. 2008;18:73–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18325754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corcoran RB, et al.  BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci. Signal. 2010;3:ra84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3372405</ArticleId>
            <ArticleId IdType="pubmed">21098728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Acharya M, et al.  αv Integrin expression by DCs is required for TH17 cell differentiation and development of experimental autoimmune encephalomyelitis in mice. J. Clin. Invest. 2010;120:4445–4452.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2993596</ArticleId>
            <ArticleId IdType="pubmed">21099114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melton AC, et al.  Expression of αvβ8 integrin on dendritic cells regulates TH17 cell development and experimental autoimmune encephalomyelitis in mice. J. Clin. Invest. 2010;120:4436–4444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2993595</ArticleId>
            <ArticleId IdType="pubmed">21099117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yadav H, et al.  Protection from obesity and diabetes by blockade of TGF-β/Smad3 signaling. Cell Metab. 2011;14:67–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3169298</ArticleId>
            <ArticleId IdType="pubmed">21723505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev. 2005;19:2783–2810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16322555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keller B, et al.  Interaction of TGFβ and BMP signaling pathways during chondrogenesis. PLoS ONE. 2011;6:e16421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3030581</ArticleId>
            <ArticleId IdType="pubmed">21297990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montero JA, Lorda-Diez CI, Ganan Y, Macias D, Hurle JM. Activin/TGFβ and BMP crosstalk determines digit chondrogenesis. Dev. Biol. 2008;321:343–356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18602912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hau P, et al.  Inhibition of TGF-2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides. 2007;17:201–212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17638524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chamberlain MC. Convection-enhanced delivery of a transforming growth factor-β2 inhibitor trabedersen for recurrent high-grade gliomas: efficacy real or imagined?, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142) Neuro Oncol. 2011;13:558–559. author reply 561-552.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3093343</ArticleId>
            <ArticleId IdType="pubmed">21558078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wick W, Weller M. Trabedersen to target transforming growth factor-β: when the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142) Neuro Oncol. 2011;13:559–560. author reply 561-552.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3093341</ArticleId>
            <ArticleId IdType="pubmed">21558079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme. J. Neurooncol. 2012;108:173–177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22382781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azaro A, et al.  The oral transforming growth factor-β (TGF-β) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: the first human dose study. J. Clin. Oncol. 2012;30 Abstract 2042.</Citation>
        </Reference>
        <Reference>
          <Citation>Occleston NL, et al.  Discovery and development of avotermin (recombinant human transforming growth factor β3): a new class of prophylactic therapeutic for the improvement of scarring. Wound Repair Regen. 2011;19(Suppl. 1):S38–S48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21793965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Platten M, et al.  N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-β relesase and reduces migration and invasiveness of human malignant glioma cells. Int. J. Cancer. 2001;93:53–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11391621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Isaji M, et al.  Inhibitory effects of tranilast on the proliferation and functions of human pterygium-derived fibroblasts. Cornea. 2000;19:364–368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10832700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schlingensiepen KH, et al.  The TGF-β1 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: preclinical studies. J. Clin. Oncol. 2004;22 Abstract 3132.</Citation>
        </Reference>
        <Reference>
          <Citation>Nam JS, et al.  Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor β in a mouse model of breast cancer. Cancer Res. 2006;66:6327–6335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1528715</ArticleId>
            <ArticleId IdType="pubmed">16778210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melisi D, et al.  LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol. Cancer Ther. 2008;7:829–840.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3088432</ArticleId>
            <ArticleId IdType="pubmed">18413796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fransvea E, Angelotti U, Antonaci S, Giannelli G. Blocking transforming growth factor-β up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology. 2008;47:1557–1566.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18318443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazzocca A, Fransvea E, Lavezzari G, Antonaci S, Giannelli G. Inhibition of transforming growth factor β receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology. 2009;50:1140–1151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19711426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang B, Halder SK, Zhang S, Datta PK. Targeting transforming growth factor-β signaling in liver metastasis of colon cancer. Cancer Lett. 2009;277:114–120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2776056</ArticleId>
            <ArticleId IdType="pubmed">19147275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inman GJ, et al.  SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 2002;62:65–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12065756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hjelmeland MD, et al.  SB-431542, a small molecule transforming growth factor-β-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol. Cancer Ther. 2004;3:737–745.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15210860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DaCosta Byfield S, Major C, Laping NJ, Roberts AB. SB-505124 is a selective inhibitor of transforming growth factor-β type I receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 2004;65:744–752.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14978253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ge R, et al.  Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-β type I receptor kinase in vivo. Clin. Cancer Res. 2006;12:4315–4330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16857807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki E, et al.  A novel small-molecule inhibitor of transforming growth factor β type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res. 2007;67:2351–2359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17332368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gellibert F, et al.  Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H-pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-β type I receptor inhibitor. J. Med. Chem. 2006;49:2210–2221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16570917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petersen M, et al.  Oral administration of GW788388, an inhibitor of TGF-β type I and II receptor kinases, decreases renal fibrosis. Kidney Int. 2008;73:705–715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18075500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan SM, Zhang Y, Connelly KA, Gilbert RE, Kelly DJ. Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 2010;298:H1415–H1425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20154262</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
